Lymphoma Trial, Recruiting NCT06386198 Sponsor: University of California, San Francisco Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06386198
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The person received a liver transplant more than 1 year ago
  • The study team has reviewed the person's situation and discussed with their main transplant doctor that they may benefit from the Health Advocate program
  • The person has an unmet social need (such as not having reliable access to food) or has scored 2.0 or higher on a specific health-related measure called the MLVI (confirm with trial site)
  • The person is expected to be moved from a pediatric (children's) transplant team to an adult transplant team within the next 6 months
  • The person is able to read and write in English or Spanish
  • The person is between 18 and 25 years old and is able to give their own consent to participate
  • The person has a working phone and a smart device (such as a smartphone or tablet) that can make video and/or audio calls using Zoom

Who may not be able to join:

  • People who have significant difficulty with thinking, memory, or understanding
  • People who do not fall within the required age range
  • People who are currently a ward of the state (meaning a government authority has legal responsibility for them)
  • People who do not speak or read English or Spanish
  • People who do not live in the United States

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sharad Wadhwani, MD, MPH, University of California, San Francisco

Phone: 510-428-3058

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 March 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in patient experience

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov